PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32551505-5 2020 The assay is capable of simultaneously quantifying multiple endogenous compounds, including IBC, thiamine, N1-methylnicotinamide (1-NMN), creatinine, carnitine, and metformin, a substrate for OCT1/2 and MATE1/2K in clinical studies. Metformin 165-174 solute carrier family 47 member 1 Homo sapiens 203-210 33262224-3 2021 In order to address if IC50 values of MATE1 inhibitors with regard to their extracellular concentrations are affected by the direction of MATE1-mediated transport, we established an efflux assay of 1-methyl-4-phenylpyridinium (MPP+) and metformin using the HEK293 model transiently expressing human MATE1. Metformin 237-246 solute carrier family 47 member 1 Homo sapiens 38-43 33262224-13 2021 This study supports the rationale for commonly accepted uptake assay with metformin as an in vitro probe substrate for MATE1-mediated DDI risk assessment in drug development. Metformin 74-83 solute carrier family 47 member 1 Homo sapiens 119-124 32472157-0 2020 A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. Metformin 109-118 solute carrier family 47 member 1 Homo sapiens 81-86 32472157-3 2020 Hepatic and renal uptake of metformin is mediated by organic cation transporter 1 (OCT1) and OCT2, respectively, and its renal excretion by multidrug and toxin extrusion 1 (MATE1) and MATE2-K. Metformin 28-37 solute carrier family 47 member 1 Homo sapiens 140-171 32472157-3 2020 Hepatic and renal uptake of metformin is mediated by organic cation transporter 1 (OCT1) and OCT2, respectively, and its renal excretion by multidrug and toxin extrusion 1 (MATE1) and MATE2-K. Metformin 28-37 solute carrier family 47 member 1 Homo sapiens 173-178 30294927-5 2018 Furthermore, the presence of nuciferine in the basal compartment caused a concentration-dependent reduction of intracellular metformin accumulation in MDCK-hOCT1/hMATE1 cell monolayers. Metformin 125-134 solute carrier family 47 member 1 Homo sapiens 162-168 30433870-1 2018 Background This work aimed to evaluate the influence of single nucleotide polymorphisms (SNPs) in the SLC47A1 (922-158G>A; rs2289669) and SLC47A2 (-130G>A; rs12943590) genes on the relative change in HbA1c in type 2 diabetes mellitus (T2DM) patients of South India who are taking metformin as monotherapy. Metformin 286-295 solute carrier family 47 member 1 Homo sapiens 102-109 32444490-0 2020 Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. Metformin 0-9 solute carrier family 47 member 1 Homo sapiens 131-136 32444490-4 2020 Mechanistically, the mutated KRAS oncoprotein hypermethylates and silences the expression of multidrug and toxic compound extrusion 1 (MATE1), a specific pump that expels metformin from the tumor cells by up-regulating DNA methyltransferase 1 (DNMT1). Metformin 171-180 solute carrier family 47 member 1 Homo sapiens 135-140 32444490-5 2020 Our findings provide evidence that KRAS-mutation mCRC patients benefit from metformin treatment and targeting MATE1 may provide a strategy to improve the anticancer response of metformin. Metformin 177-186 solute carrier family 47 member 1 Homo sapiens 110-115 31012983-1 2019 The organic cation transporters OCT1 and OCT2 and the multidrug and toxin extrusion transporter MATE1, encoded by the SLC22A1, SLC22A2, and SLC47A1 genes, respectively, are responsible for the absorption of metformin in enterocytes, hepatocytes, and kidney cells. Metformin 207-216 solute carrier family 47 member 1 Homo sapiens 96-101 31012983-1 2019 The organic cation transporters OCT1 and OCT2 and the multidrug and toxin extrusion transporter MATE1, encoded by the SLC22A1, SLC22A2, and SLC47A1 genes, respectively, are responsible for the absorption of metformin in enterocytes, hepatocytes, and kidney cells. Metformin 207-216 solute carrier family 47 member 1 Homo sapiens 140-147 31012983-2 2019 The aim of this study was to evaluate whether genetic variations in the SLC22A1, SLC22A2, and SLC47A1 genes could be associated with an altered response to metformin in patients with type 2 diabetes mellitus. Metformin 156-165 solute carrier family 47 member 1 Homo sapiens 94-101 29480578-4 2018 HCT inhibited human OCT2 and human MATE1-mediated metformin transports in vitro. Metformin 50-59 solute carrier family 47 member 1 Homo sapiens 35-40 29862627-8 2018 Gene knockdown by RNAi showed that MATE1 and PMAT reduction attenuated the antilipolytic effect of metformin but only PMAT knockdown decreased the effect of all three biguanides. Metformin 99-108 solute carrier family 47 member 1 Homo sapiens 35-40 30191328-3 2018 METHODS: The inhibition by select compounds on the uptake of the probe substrate metformin was assessed in HEK293 cells overexpressing human OCT2, OCT1, MATE1, MATE2-K, and mouse Oct2, Oct1, and Mate1. Metformin 81-90 solute carrier family 47 member 1 Homo sapiens 153-158 28321905-0 2017 Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes. Metformin 180-189 solute carrier family 47 member 1 Homo sapiens 77-84 28947922-6 2017 Lower average and promoter DNA methylation of SLC22A1, SLC22A3, and SLC47A1 was found in diabetic subjects receiving just metformin, compared to those who took insulin plus metformin or no diabetes medication. Metformin 122-131 solute carrier family 47 member 1 Homo sapiens 68-75 28947922-6 2017 Lower average and promoter DNA methylation of SLC22A1, SLC22A3, and SLC47A1 was found in diabetic subjects receiving just metformin, compared to those who took insulin plus metformin or no diabetes medication. Metformin 173-182 solute carrier family 47 member 1 Homo sapiens 68-75 28971610-0 2017 Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. Metformin 184-193 solute carrier family 47 member 1 Homo sapiens 106-130 28971610-4 2017 Subsequently, to understand whether inhibition of renal transporters are responsible for AUC increases, in vitro inhibitory potencies against metformin transport by human OCT2, multidrug and toxin extrusion (MATE) 1 and MATE2-K were determined. Metformin 142-151 solute carrier family 47 member 1 Homo sapiens 191-215 28971610-6 2017 Calculated theoretical fold-increases in metformin exposure confirmed solitary inhibition of renal MATE1 to be the likely mechanism underlying the observed exposure changes in clinical DDIs. Metformin 41-50 solute carrier family 47 member 1 Homo sapiens 99-104 28321905-1 2017 AIM: To elucidate the effects of rs2289669, an intron variant of the SLC47A1 gene, on glucose response to metformin in Chinese people with newly diagnosed Type 2 diabetes. Metformin 106-115 solute carrier family 47 member 1 Homo sapiens 69-76 28069720-2 2017 As pregnancy increased the renal secretion of metformin, a substrate for OCT2, MATE1, and MATE2-K, we hypothesized that the renal secretion of 1-NMN would be similarly affected. Metformin 46-55 solute carrier family 47 member 1 Homo sapiens 79-84 28546950-2 2017 SLC47A1 (MATE1) and SLC47A2 (MATE2) are major efflux transporters involved in the hepatic and renal excretion of many cationic drugs including metformin. Metformin 143-152 solute carrier family 47 member 1 Homo sapiens 0-7 28546950-2 2017 SLC47A1 (MATE1) and SLC47A2 (MATE2) are major efflux transporters involved in the hepatic and renal excretion of many cationic drugs including metformin. Metformin 143-152 solute carrier family 47 member 1 Homo sapiens 9-14 27324407-8 2016 The LSS model reproduced previously reported results for effects of polymorphisms in OCT2 and MATE1 genes on AUC(0,24 h) and renal clearance of metformin. Metformin 144-153 solute carrier family 47 member 1 Homo sapiens 94-99 27871888-7 2017 Cd2+ could inhibit the uptake of metformin, a substrate of MATE transporters, with the half maximal inhibitory concentration (IC50) of 97.5+-6.0muM, 20.2+-2.6muM, and 49.9+-6.9muM in HEK-hMATE1, HEK-hMATE2-K, and HEK-mMate1 cells, respectively. Metformin 33-42 solute carrier family 47 member 1 Homo sapiens 187-193 27019345-4 2016 The models were used to simulate inhibition of the MATE1, MATE2-K, OCT1 and OCT2 mediated transport of metformin by cimetidine. Metformin 103-112 solute carrier family 47 member 1 Homo sapiens 51-56 27555891-7 2016 Inter-individual variability in response to OADs is due to polymorphisms in genes encoding drug receptors, transporters, and metabolizing enzymes for example, genetic variants in solute carrier transporters (SLC22A1, SLC22A2, SLC22A3, SLC47A1 and SLC47A2) are actively involved in glycemic/HbA1c management of metformin. Metformin 310-319 solute carrier family 47 member 1 Homo sapiens 235-242 26597253-0 2016 The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Metformin 103-112 solute carrier family 47 member 1 Homo sapiens 28-33 26597253-2 2016 The goal of our study was to determine the effects of selective inhibition of multidrug and toxin extrusion protein 1 (MATE1), using famotidine, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Metformin 193-202 solute carrier family 47 member 1 Homo sapiens 78-117 26597253-2 2016 The goal of our study was to determine the effects of selective inhibition of multidrug and toxin extrusion protein 1 (MATE1), using famotidine, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers. Metformin 193-202 solute carrier family 47 member 1 Homo sapiens 119-124 26977146-0 2016 The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. Metformin 71-80 solute carrier family 47 member 1 Homo sapiens 36-43 27180666-5 2016 The response to metformin treatment was associated with the genetic variants ATM and SLC47A1. Metformin 16-25 solute carrier family 47 member 1 Homo sapiens 85-92 26784938-0 2016 The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment. Metformin 64-73 solute carrier family 47 member 1 Homo sapiens 4-9 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 47 member 1 Homo sapiens 15-53 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 47 member 1 Homo sapiens 55-60 26784938-1 2016 PURPOSE: Human multidrug and toxin extrusion member 1 (MATE1, SLC47A1) and Organic Cation Transporter 2 (OCT2, SLC22A2) play important roles in the renal elimination of various pharmacologic agents, including the anti-diabetic drug metformin. Metformin 232-241 solute carrier family 47 member 1 Homo sapiens 62-69 26784938-2 2016 The goal of this study was to determine the association between metformin"s pharmacokinetics and pharmacodynamics and the genetic variants of MATE1 (rs2289669) and OCT2 (rs316019) before and after treatment with the potential MATE inhibitor, ranitidine. Metformin 64-73 solute carrier family 47 member 1 Homo sapiens 142-147 26784938-5 2016 However, the renal clearance of metformin was significantly higher (15.2%) after ranitidine treatment in the MATE1 GG group compared with the MATE1 GA + AA group. Metformin 32-41 solute carrier family 47 member 1 Homo sapiens 109-114 26784938-5 2016 However, the renal clearance of metformin was significantly higher (15.2%) after ranitidine treatment in the MATE1 GG group compared with the MATE1 GA + AA group. Metformin 32-41 solute carrier family 47 member 1 Homo sapiens 142-147 26784938-6 2016 Only the effect of MATE1 on the renal clearance of metformin after ranitidine treatment was significant (b = -0.465, p <= 0.05) after including demographic data and the OCT2 genotype in the model. Metformin 51-60 solute carrier family 47 member 1 Homo sapiens 19-24 26784938-7 2016 CONCLUSION: Our study suggests that MATE1 rs2289669 may be a significant determinant in the renal clearance of metformin in the case of transporter-mediated drug interactions. Metformin 111-120 solute carrier family 47 member 1 Homo sapiens 36-41 26977146-2 2016 We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Metformin 136-145 solute carrier family 47 member 1 Homo sapiens 81-88 26977146-13 2016 Our data suggest that SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms may influence metformin efficacy together in Chinese T2DM patients. Metformin 89-98 solute carrier family 47 member 1 Homo sapiens 43-50 26426900-5 2015 OCT1-, OCT2-, MATE1- and MATE2-K-mediated metformin uptake was significantly reduced in the presence of green tea and EGCG (P < 0.05). Metformin 42-51 solute carrier family 47 member 1 Homo sapiens 14-19 26004431-0 2015 SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Metformin 78-87 solute carrier family 47 member 1 Homo sapiens 0-7 26004431-10 2015 CONCLUSIONS: SLC47A1 rs2289669 G>A variants improve the glucose-lowering effect of metformin through slowing its excretion in type 2 diabetes populations. Metformin 86-95 solute carrier family 47 member 1 Homo sapiens 13-20 26004431-1 2015 AIMS: The SLC47A1 gene encodes the multi-drug and toxic excretion-1(MATE1) protein, which plays a key role in the transport and excretion of metformin. Metformin 141-150 solute carrier family 47 member 1 Homo sapiens 10-17 26004431-1 2015 AIMS: The SLC47A1 gene encodes the multi-drug and toxic excretion-1(MATE1) protein, which plays a key role in the transport and excretion of metformin. Metformin 141-150 solute carrier family 47 member 1 Homo sapiens 68-73 26004431-2 2015 This study is to clarify the influence of variants in SLC47A1 (rs2289669 G A) on metformin pharmacokinetics and the long-term glucose-lowering effect of metformin. Metformin 81-90 solute carrier family 47 member 1 Homo sapiens 54-61 26004431-2 2015 This study is to clarify the influence of variants in SLC47A1 (rs2289669 G A) on metformin pharmacokinetics and the long-term glucose-lowering effect of metformin. Metformin 153-162 solute carrier family 47 member 1 Homo sapiens 54-61 26004431-8 2015 Pharmacokinetic parameters of metformin indicated that patients carrying MATE1 homozygous A had higher area under the plasma concentration versus time curve (AUC12h), but lower renal clearance (CLR) and renal clearance by secretion (CLSR) than other patients (all P<0.01). Metformin 30-39 solute carrier family 47 member 1 Homo sapiens 73-78 26004431-9 2015 Multivariate lineal stepwise analysis further revealed that SLC47A1 genotype was an independent impact factor for urine excretion of metformin (P<0.01). Metformin 133-142 solute carrier family 47 member 1 Homo sapiens 60-67 24238901-1 2013 In order to develop a new positron emission tomography (PET) probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1), (11)C-labelled metformin was synthesized and then evaluated as a PET probe. Metformin 185-194 solute carrier family 47 member 1 Homo sapiens 162-167 26552145-6 2015 The cellular accumulation of metformin in MDCK-hMATE1 was 17.6 folds of the control cell, which was significantly inhibited by 100 micromol L(-1) cimetidine. Metformin 29-38 solute carrier family 47 member 1 Homo sapiens 47-53 25753371-0 2015 Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Metformin 149-158 solute carrier family 47 member 1 Homo sapiens 0-31 25753371-1 2015 BACKGROUND: This study was initiated to explore the impact of organic cation transporter 1 (OCT1) and multidrug and toxin extrusion transporter 1 (MATE1) genetic polymorphisms on toxicity, and clinical activity of metformin in patients with castration-resistant prostate cancer (CRPC). Metformin 214-223 solute carrier family 47 member 1 Homo sapiens 147-152 25394090-3 2014 In vitro, DTG inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE 1) which are known to be involved in the disposition of metformin. Metformin 169-178 solute carrier family 47 member 1 Homo sapiens 63-106 25394090-3 2014 In vitro, DTG inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE 1) which are known to be involved in the disposition of metformin. Metformin 169-178 solute carrier family 47 member 1 Homo sapiens 108-114 25125398-1 2014 A high throughput LC-MS/MS method for quantification of metformin substrate uptake enables conversion of radiometric transporter inhibition assays for multidrug and toxin extrusion transporters (MATE 1 and 2) and organic cation transporter 2 (OCT2) to a nonradioactive format. Metformin 56-65 solute carrier family 47 member 1 Homo sapiens 195-207 23558289-1 2013 Multidrug and toxin extrusion 1 (MATE1, SLC47A1), an organic cation transporter, plays an important role in the renal and biliary elimination of various clinical drugs, including the anti-diabetic drug metformin. Metformin 202-211 solute carrier family 47 member 1 Homo sapiens 0-31 24026623-3 2013 However, vandetanib was an even more potent inhibitor of MATE1- and MATE2K-mediated uptake of MPP(+) (IC(50) of 1.23 +- 0.05 and 1.26 +- 0.06 microM, respectively) and metformin (IC(50) of 0.16 +- 0.05 and 0.30 +- 0.09 microM, respectively). Metformin 168-177 solute carrier family 47 member 1 Homo sapiens 57-62 23305245-2 2013 The aim of this study was to investigate the effects of trimethoprim on metformin pharmacokinetics and genetic modulation by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion 1 (MATE1) polymorphisms. Metformin 72-81 solute carrier family 47 member 1 Homo sapiens 198-203 23873119-0 2013 A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Metformin 108-117 solute carrier family 47 member 1 Homo sapiens 62-67 23873119-1 2013 OBJECTIVE: The aim of this study was to determine the association between the renal clearance (CL(renal)) of metformin in healthy Caucasian volunteers and the single-nucleotide polymorphism (SNP) c.808G>T (rs316019) in OCT2 as well as the relevance of the gene-gene interactions between this SNP and (a) the promoter SNP g.-66T>C (rs2252281) in MATE1 and (b) the OCT1 reduced-function diplotypes. Metformin 109-118 solute carrier family 47 member 1 Homo sapiens 351-356 23558289-1 2013 Multidrug and toxin extrusion 1 (MATE1, SLC47A1), an organic cation transporter, plays an important role in the renal and biliary elimination of various clinical drugs, including the anti-diabetic drug metformin. Metformin 202-211 solute carrier family 47 member 1 Homo sapiens 33-38 23558289-1 2013 Multidrug and toxin extrusion 1 (MATE1, SLC47A1), an organic cation transporter, plays an important role in the renal and biliary elimination of various clinical drugs, including the anti-diabetic drug metformin. Metformin 202-211 solute carrier family 47 member 1 Homo sapiens 40-47 19228809-0 2009 Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Metformin 119-128 solute carrier family 47 member 1 Homo sapiens 25-56 23267855-4 2013 The renal and secretory clearances of metformin were higher (22% and 26%, respectively) in carriers of variant MATE2 who were also MATE1 reference (P < 0.05). Metformin 38-47 solute carrier family 47 member 1 Homo sapiens 131-136 23267855-5 2013 Both MATE genotypes were associated with altered post-metformin glucose tolerance, with variant carriers of MATE1 and MATE2 having an enhanced (P < 0.01) and reduced (P < 0.05) response, respectively. Metformin 54-63 solute carrier family 47 member 1 Homo sapiens 108-113 23267855-6 2013 Consistent with these results, patients with diabetes (n = 145) carrying the MATE1 variant showed enhanced metformin response. Metformin 107-116 solute carrier family 47 member 1 Homo sapiens 77-82 23267855-7 2013 These findings suggest that promoter variants of MATE1 and MATE2 are important determinants of metformin disposition and response in healthy volunteers and diabetic patients. Metformin 95-104 solute carrier family 47 member 1 Homo sapiens 49-54 22882994-0 2013 Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Metformin 90-99 solute carrier family 47 member 1 Homo sapiens 49-56 22882994-2 2013 The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporters-solute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes. Metformin 254-263 solute carrier family 47 member 1 Homo sapiens 191-226 22882994-2 2013 The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporters-solute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes. Metformin 254-263 solute carrier family 47 member 1 Homo sapiens 228-235 24324494-5 2013 SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. Metformin 88-97 solute carrier family 47 member 1 Homo sapiens 9-16 22735389-2 2012 So far, the number of polymorphisms in SLC22A1, SLC22A2, and SLC47A1 genes coding for organic cation transporter 1 (OCT1), OCT2, and multidrug and toxin extrusion transporter 1 (MATE1) metformin transporters have been described in association with the efficacy of metformin. Metformin 185-194 solute carrier family 47 member 1 Homo sapiens 61-68 22735389-2 2012 So far, the number of polymorphisms in SLC22A1, SLC22A2, and SLC47A1 genes coding for organic cation transporter 1 (OCT1), OCT2, and multidrug and toxin extrusion transporter 1 (MATE1) metformin transporters have been described in association with the efficacy of metformin. Metformin 185-194 solute carrier family 47 member 1 Homo sapiens 133-176 21923552-3 2011 Two isoforms, MATE1 and 2, have been identified, and, so far, only a limited number of substrates, including clinically used drugs such as metformin and cimetidine, are known. Metformin 139-148 solute carrier family 47 member 1 Homo sapiens 14-25 21241070-15 2011 An intron variant of multidrug and toxin extrusion transporter [MATE1] (G>A, SNP rs2289669) has also been associated with a small increase in antihyperglycaemic effect of metformin. Metformin 174-183 solute carrier family 47 member 1 Homo sapiens 64-69 20682687-6 2010 RESULTS: We replicated the association of variants in the metformin transporter gene SLC47A1 with metformin response and detected nominal interactions in the AMP kinase (AMPK) gene STK11, the AMPK subunit genes PRKAA1 and PRKAA2, and a missense SNP in SLC22A1, which encodes another metformin transporter. Metformin 58-67 solute carrier family 47 member 1 Homo sapiens 85-92 23267855-0 2013 The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Metformin 105-114 solute carrier family 47 member 1 Homo sapiens 41-46 23894862-5 2013 For example, genetic variations of several membrane transporters, including SLC2A1/2 and SLC47A1/2 genes, are implicated in the highly variable glycemic response to metformin, a first-line drug used to treat newly diagnosed T2DM. Metformin 165-174 solute carrier family 47 member 1 Homo sapiens 89-96 21989078-1 2011 OBJECTIVE: The aim of this study was to evaluate the effect of genetic variations in OCT1, OCT2, MATE1, MATE 2, and PMAT on the trough steady-state plasma concentration of metformin and hemoglobin A1c (Hb1Ac). Metformin 172-181 solute carrier family 47 member 1 Homo sapiens 97-102 20883471-6 2011 Over a wide concentration range (10-2500 microM) metformin transcellular transport from the basal into the apical compartment was significantly higher in the double-transfected cells compared with the MDCK control and MDCK-MATE1 monolayers. Metformin 49-58 solute carrier family 47 member 1 Homo sapiens 223-228 20883471-8 2011 In MDCK-OCT2-MATE1 cells basal to apical MPP(+) and metformin transcellular translocation decreased with increasing pH from 6.0 to 7.5. Metformin 52-61 solute carrier family 47 member 1 Homo sapiens 13-18 21677353-9 2011 However, MATE1 transporter (multidrug and toxin extrusion 1 protein) is encoded by the SLC47A1 gene and facilitates metformin excretion from these cells into bile and urine. Metformin 116-125 solute carrier family 47 member 1 Homo sapiens 9-14 21677353-9 2011 However, MATE1 transporter (multidrug and toxin extrusion 1 protein) is encoded by the SLC47A1 gene and facilitates metformin excretion from these cells into bile and urine. Metformin 116-125 solute carrier family 47 member 1 Homo sapiens 87-94 20016398-1 2010 Multidrug and toxin extrusions (MATE1/SLC47A1 and MATE2-K/SLC47A2) play important roles in the renal excretion of metformin. Metformin 114-123 solute carrier family 47 member 1 Homo sapiens 32-37 20016398-1 2010 Multidrug and toxin extrusions (MATE1/SLC47A1 and MATE2-K/SLC47A2) play important roles in the renal excretion of metformin. Metformin 114-123 solute carrier family 47 member 1 Homo sapiens 38-45 19898263-0 2010 Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Metformin 72-81 solute carrier family 47 member 1 Homo sapiens 50-55 19898263-1 2010 OBJECTIVE: Metformin is transported into the hepatocyte by organic cation transporter 1 (OCT1) and out of the hepatocyte by multidrug and toxin extrusion 1 (MATE1). Metformin 11-20 solute carrier family 47 member 1 Homo sapiens 124-155 19898263-1 2010 OBJECTIVE: Metformin is transported into the hepatocyte by organic cation transporter 1 (OCT1) and out of the hepatocyte by multidrug and toxin extrusion 1 (MATE1). Metformin 11-20 solute carrier family 47 member 1 Homo sapiens 157-162 19898263-2 2010 Recently, we discovered that polymorphisms rs622342 A>C in the SLC22A1 gene, coding for OCT1, and rs2289669 G>A in the SLC47A1 gene, coding for MATE1, are associated with the degree of glucose lowering by metformin. Metformin 211-220 solute carrier family 47 member 1 Homo sapiens 125-132 19898263-9 2010 CONCLUSION: The effect of the MATE1 rs2289669 polymorphism on the glucose lowering effect of metformin is larger in incident users with the OCT1 rs622342 CC genotype than in incident users with the AA genotype. Metformin 93-102 solute carrier family 47 member 1 Homo sapiens 30-35 19164462-0 2009 Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. Metformin 100-109 solute carrier family 47 member 1 Homo sapiens 21-52 19228809-2 2009 In these cells, the multidrug and toxin extrusion (MATE) 1 protein, encoded by the SLC47A1 gene, is responsible for the excretion of metformin into the bile and urine, respectively. Metformin 133-142 solute carrier family 47 member 1 Homo sapiens 20-29 19228809-2 2009 In these cells, the multidrug and toxin extrusion (MATE) 1 protein, encoded by the SLC47A1 gene, is responsible for the excretion of metformin into the bile and urine, respectively. Metformin 133-142 solute carrier family 47 member 1 Homo sapiens 51-58 19228809-2 2009 In these cells, the multidrug and toxin extrusion (MATE) 1 protein, encoded by the SLC47A1 gene, is responsible for the excretion of metformin into the bile and urine, respectively. Metformin 133-142 solute carrier family 47 member 1 Homo sapiens 83-90 19228809-3 2009 We studied the effect of single nucleotide polymorphisms (SNPs) in the SLC47A1 gene on the A1C-lowering effect of metformin. Metformin 114-123 solute carrier family 47 member 1 Homo sapiens 71-78 19228809-12 2009 These results suggest that the transporter MATE1, encoded by SLC47A1, may have an important role in the pharmacokinetics of metformin, although replication is necessary. Metformin 124-133 solute carrier family 47 member 1 Homo sapiens 43-48 19228809-12 2009 These results suggest that the transporter MATE1, encoded by SLC47A1, may have an important role in the pharmacokinetics of metformin, although replication is necessary. Metformin 124-133 solute carrier family 47 member 1 Homo sapiens 61-68 34388523-0 2021 The L125F MATE1 variant enriched in populations of Amerindian origin is associated with increased plasma levels of metformin and lactate. Metformin 115-124 solute carrier family 47 member 1 Homo sapiens 10-15 17509534-5 2007 Kinetic analyses demonstrated the Michaelis-Menten constants for the hMATE1-mediated transport of tetraethylammonium, 1-methyl-4-phenylpyridinium, cimetidine, metformin, guanidine, procainamide, topotecan, estrone sulfate, acycrovir, and ganciclovir to be (in mM) 0.38, 0.10, 0.17, 0.78, 2.10, 1.23, 0.07, 0.47, 2.64, and 5.12, respectively. Metformin 159-168 solute carrier family 47 member 1 Homo sapiens 69-75 34388523-2 2021 Metformin pharmacokinetics is carried out by members of the membrane transporters superfamily (SLCs), being the multidrug and toxin extrusion protein 1 (MATE1), one of the most studied. Metformin 0-9 solute carrier family 47 member 1 Homo sapiens 112-151 34388523-2 2021 Metformin pharmacokinetics is carried out by members of the membrane transporters superfamily (SLCs), being the multidrug and toxin extrusion protein 1 (MATE1), one of the most studied. Metformin 0-9 solute carrier family 47 member 1 Homo sapiens 153-158 34388523-3 2021 Some genetic variants in MATE1 have been associated with reduced in vitro metformin transport. Metformin 74-83 solute carrier family 47 member 1 Homo sapiens 25-30 34388523-6 2021 To elucidate the metformin pharmacogenetics, a children cohort was genotyped, allowing us to describe, for the first time, a MATE1 rs77474263 TT homozygous individual. Metformin 17-26 solute carrier family 47 member 1 Homo sapiens 125-130 34151116-4 2021 To find a potential explanation for this practice, we employed atomistic-level computer simulations to simulate the transport of metformin through multidrug and toxin extrusion 1 (MATE1), a protein known to play a key role in the expulsion of metformin into urine. Metformin 129-138 solute carrier family 47 member 1 Homo sapiens 147-178 34097256-0 2021 Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. Metformin 56-65 solute carrier family 47 member 1 Homo sapiens 89-94 34505146-0 2022 Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. Metformin 19-28 solute carrier family 47 member 1 Homo sapiens 69-76 34505146-1 2022 Several pharmacogenetics studies have identified an association between a greater metformin-dependent reduction in HbA1c levels and the minor A allele at rs2289669 in intron 10 of SLC47A1, encoding multidrug and toxin extrusion 1 (MATE1), a presumed metformin transporter. Metformin 82-91 solute carrier family 47 member 1 Homo sapiens 180-187 34505146-1 2022 Several pharmacogenetics studies have identified an association between a greater metformin-dependent reduction in HbA1c levels and the minor A allele at rs2289669 in intron 10 of SLC47A1, encoding multidrug and toxin extrusion 1 (MATE1), a presumed metformin transporter. Metformin 82-91 solute carrier family 47 member 1 Homo sapiens 198-229 34505146-1 2022 Several pharmacogenetics studies have identified an association between a greater metformin-dependent reduction in HbA1c levels and the minor A allele at rs2289669 in intron 10 of SLC47A1, encoding multidrug and toxin extrusion 1 (MATE1), a presumed metformin transporter. Metformin 82-91 solute carrier family 47 member 1 Homo sapiens 231-236 34505146-3 2022 We looked at association between common genetic variants in the SLC47A1 gene region and HbA1c reduction after metformin treatment using locus-wise meta-analysis from the MetGen consortium. Metformin 110-119 solute carrier family 47 member 1 Homo sapiens 64-71 34151116-4 2021 To find a potential explanation for this practice, we employed atomistic-level computer simulations to simulate the transport of metformin through multidrug and toxin extrusion 1 (MATE1), a protein known to play a key role in the expulsion of metformin into urine. Metformin 129-138 solute carrier family 47 member 1 Homo sapiens 180-185 34151116-4 2021 To find a potential explanation for this practice, we employed atomistic-level computer simulations to simulate the transport of metformin through multidrug and toxin extrusion 1 (MATE1), a protein known to play a key role in the expulsion of metformin into urine. Metformin 243-252 solute carrier family 47 member 1 Homo sapiens 147-178 34151116-4 2021 To find a potential explanation for this practice, we employed atomistic-level computer simulations to simulate the transport of metformin through multidrug and toxin extrusion 1 (MATE1), a protein known to play a key role in the expulsion of metformin into urine. Metformin 243-252 solute carrier family 47 member 1 Homo sapiens 180-185 34151116-5 2021 Herein, we examine the hydrogen bonding between MATE1 and one or more metformin molecules. Metformin 70-79 solute carrier family 47 member 1 Homo sapiens 48-53 34151116-6 2021 The simulation results indicate that metformin continuously forms and breaks off hydrogen bonds with MATE1 residues. Metformin 37-46 solute carrier family 47 member 1 Homo sapiens 101-106 34265779-7 2021 Variants on SLC47A1, SLC28A1, and ABCG2 likely impact the pharmacokinetics (PK) of metformin, while the role of the two latter can be related to insulin resistance and regulation of adipogenesis. Metformin 83-92 solute carrier family 47 member 1 Homo sapiens 12-19 35183887-11 2022 Altogether, our data suggest that tamsulosin could increase systemic exposure and reduce excretion of metformin via inhibiting Oct2 and Mate1-mediated transport cooperatively. Metformin 102-111 solute carrier family 47 member 1 Homo sapiens 136-141 35042121-10 2022 The inhibitor sensitivity of MATE1-facilitated amiloride transport was similar to those of known substrates, such as tetraethylammonium and metformin. Metformin 140-149 solute carrier family 47 member 1 Homo sapiens 29-34 35163393-7 2022 Dividing these values into the different Jmax values for transport of MPP, metformin, and atenolol mediated by MATE1 and OCT2 resulted in calculated TOR values (+-SE, n = 4) of 84.0 +- 22.0 s-1 and 2.9 +- 0.6 s-1; metformin, 461.0 +- 121.0 s-1 and 12.6 +- 2.4 s-1; atenolol, 118.0 +- 31.0 s-1, respectively. Metformin 75-84 solute carrier family 47 member 1 Homo sapiens 111-116 35163393-7 2022 Dividing these values into the different Jmax values for transport of MPP, metformin, and atenolol mediated by MATE1 and OCT2 resulted in calculated TOR values (+-SE, n = 4) of 84.0 +- 22.0 s-1 and 2.9 +- 0.6 s-1; metformin, 461.0 +- 121.0 s-1 and 12.6 +- 2.4 s-1; atenolol, 118.0 +- 31.0 s-1, respectively. Metformin 214-223 solute carrier family 47 member 1 Homo sapiens 111-116